Need Help?

Whole genome sequencing and whole exome sequencing of DIPG tumors and matched normal tissue

Diffuse Intrinsic Pontine Glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children with no effective treatment. To understand what drives DIPGs we integrated whole-genome-sequencing with methylation, expression and copy-number profiling.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000814 40
EGAD00001003305 AB SOLiD System Illumina HiSeq 2500 23
Publications Citations
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.
Nat Genet 46: 2014 451-456
463
ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability.
Mol Cell Oncol 3: 2016 e1167158
46
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Oncotarget 7: 2016 65696-65706
54
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.
Cancer Cell 32: 2017 520-537.e5
816
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.
Nat Med 24: 2018 1204-1215
137
ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
Cell Rep 38: 2022 110216
45
Splicing is an alternate oncogenic pathway activation mechanism in glioma.
Nat Commun 13: 2022 588
32
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Neuro Oncol 25: 2023 54-67
13
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.
Nat Cancer 3: 2022 994-1011
33
Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.
Nucleic Acids Res 52: 2024 2372-2388
17
Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment.
Nat Commun 15: 2024 5790
13
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma.
Nat Commun 15: 2024 8983
8
The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases.
Neuro Oncol 27: 2025 1829-1846
1